WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference ...

Apellis Pharmaceuticals ( (APLS) ) has released its Q3 earnings. Here is a breakdown of the information Apellis Pharmaceuticals presented to ...

The best logo maker is essential for branding your business and standing out online. My team and I have tested the top tools for beginners and professional designers, and everyone in between.

The best free logo maker delivers a creative space for designing a logo that helps your business stand out. I've been using online design apps for over ten years, and these are my top ...

Overall, Apellis reported total third-quarter revenues of $196.8 million, up 78% year over year. Beyond Syfovre, the company’s paroxysmal nocturnal hemoglobinuria drug Empaveli grew sales 0.4% ...

Apellis Pharmaceuticals, Inc. (APLS) reported $196.83 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 78.3%. EPS of -$0.46 for the same period ...

Based on the one-year price targets offered by 18 analysts, the average target price for Apellis Pharmaceuticals Inc (NASDAQ:APLS) is $62.94 with a high estimate of $95 and a low estimate of $25.

Unfortunately for investors, it missed on both the top and bottom lines. Apellis unveiled those results before market hours on Tuesday, disclosing that its revenue for the quarter was just under ...

Apellis Pharmaceuticals (NASDAQ:APLS) shares fell sharply on Tuesday after the Waltham, Massachusetts-based biotech reported lower-than-expected Q3 2024 financials as U.S. net sales from its eye ...